Akoya Biosciences Announces Scott Mendel as Chairman of the Board of Directors
Akoya Biosciences, Inc. (Nasdaq: AKYA) has announced the appointment of Scott Mendel as Chairman of its Board of Directors, effective October 2, 2024. Mendel, who has been a board member since June 2021, succeeds Robert Shepler, the founding Chairman who will remain on the board. With over 30 years of financial and operational management experience, Mendel previously served as President and CEO of GenMark Diagnostics until its $1.8 billion acquisition by Roche in 2021.
Mendel's extensive background includes roles at The Active Network and General Electric's Healthcare IT division. He currently serves on the boards of Quantum-Si Incorporated and Pattern Biosciences. Akoya's CEO, Brian McKelligon, expressed confidence in Mendel's leadership, citing his operational expertise and industry experience as valuable assets for the company's future growth in the Spatial Biology sector.
Akoya Biosciences, Inc. (Nasdaq: AKYA) ha annunciato la nomina di Scott Mendel come Presidente del Consiglio di Amministrazione, con effetto dal 2 ottobre 2024. Mendel, che è stato un membro del consiglio da giugno 2021, succede a Robert Shepler, il Presidente fondatore che rimarrà nel consiglio. Con oltre 30 anni di esperienza nella gestione finanziaria e operativa, Mendel ha precedentemente ricoperto il ruolo di Presidente e CEO di GenMark Diagnostics fino alla sua acquisizione da 1,8 miliardi di dollari da parte di Roche nel 2021.
Il vasto background di Mendel include ruoli presso The Active Network e la divisione Healthcare IT di General Electric. Attualmente, ricopre anche cariche nei consigli di Quantum-Si Incorporated e Pattern Biosciences. Il CEO di Akoya, Brian McKelligon, ha espresso fiducia nella leadership di Mendel, citando la sua expertise operativa e l'esperienza nel settore come risorse preziose per la crescita futura dell'azienda nel settore della Biologia Spaziale.
Akoya Biosciences, Inc. (Nasdaq: AKYA) ha anunciado el nombramiento de Scott Mendel como Presidente de su Junta Directiva, con efecto a partir del 2 de octubre de 2024. Mendel, quien ha sido miembro de la junta desde junio de 2021, sucede a Robert Shepler, el Presidente fundador que permanecerá en la junta. Con más de 30 años de experiencia en gestión financiera y operativa, Mendel se desempeñó previamente como Presidente y CEO de GenMark Diagnostics hasta su adquisición por 1.8 mil millones de dólares por Roche en 2021.
El extenso historial de Mendel incluye roles en The Active Network y en la división de TI en salud de General Electric. Actualmente, también forma parte de las juntas de Quantum-Si Incorporated y Pattern Biosciences. El CEO de Akoya, Brian McKelligon, expresó confianza en el liderazgo de Mendel, citando su experiencia operativa y su conocimiento del sector como activos valiosos para el futuro crecimiento de la empresa en el sector de la Biología Espacial.
아코야 바이오사이언스(Akoya Biosciences, Inc.)(나스닥: AKYA)는 스콧 멘델(Scott Mendel)을 이사회 의장으로 임명했다고 2024년 10월 2일부로 발표했습니다. 멘델은 2021년 6월부터 이사로 활동해왔으며, 창립 의장인 로버트 셰플러(Robert Shepler)를 이어받습니다. 30년 이상의 금융 및 운영 관리 경험을 가진 멘델은 2021년 로슈(Roche)에 18억 달러에 인수되기 전까지 젠마크 다이아그노스틱스(GenMark Diagnostics)의 사장 겸 CEO로 재직했습니다.
멘델의 광범위한 배경에는 액티브 네트워크(The Active Network)와 제너럴 일렉트릭 헬스케어 IT 부서에서의 역할이 포함됩니다. 현재 그는 Quantum-Si Incorporated와 Pattern Biosciences의 이사회에서도 활동하고 있습니다. 아코야의 CEO인 브라이언 맥켈리건(Brian McKelligon)은 멘델의 리더십에 대한 신뢰를 표시하며, 그의 운영 전문성과 업계 경험이 회사의 공간 생물학(Spatial Biology) 부문에서의 미래 성장에 중요한 자산이라고 언급했습니다.
Akoya Biosciences, Inc. (Nasdaq: AKYA) a annoncé la nomination de Scott Mendel en tant que Président de son Conseil d'Administration, avec effet au 2 octobre 2024. Mendel, qui est membre du conseil depuis juin 2021, succède à Robert Shepler, le Président fondateur qui restera au conseil. Fort de plus de 30 ans d'expérience en gestion financière et opérationnelle, Mendel a précédemment été Président et CEO de GenMark Diagnostics jusqu'à son acquisition par Roche pour 1,8 milliard de dollars en 2021.
Le large éventail d'expériences de Mendel comprend des rôles au sein de The Active Network et de la division Healthcare IT de General Electric. Il siège actuellement également au conseil d'administration de Quantum-Si Incorporated et de Pattern Biosciences. Le CEO d'Akoya, Brian McKelligon, a exprimé sa confiance dans le leadership de Mendel, citant son expertise opérationnelle et son expérience dans l'industrie comme des atouts précieux pour la croissance future de l'entreprise dans le secteur de la Biologie Spatiale.
Akoya Biosciences, Inc. (Nasdaq: AKYA) hat die Ernennung von Scott Mendel zum Vorsitzenden des Board of Directors bekannt gegeben, die am 2. Oktober 2024 wirksam wird. Mendel, der seit Juni 2021 Mitglied des Vorstands ist, folgt auf Robert Shepler, den Gründungspräsidenten, der weiterhin im Board bleiben wird. Mit über 30 Jahren Erfahrung im Finanz- und Betriebsmanagement war Mendel zuvor Präsident und CEO von GenMark Diagnostics bis zur Übernahme durch Roche für 1,8 Milliarden Dollar im Jahr 2021.
Mendels umfassende Erfahrung umfasst Positionen bei The Active Network und der Healthcare-IT-Division von General Electric. Derzeit ist er auch in den Vorständen von Quantum-Si Incorporated und Pattern Biosciences tätig. Der CEO von Akoya, Brian McKelligon, äußerte sich zuversichtlich hinsichtlich Mendels Führung und nannte seine operative Expertise und Branchenerfahrung wertvolle Vermögenswerte für das zukünftige Wachstum des Unternehmens im Bereich der räumlichen Biologie.
- Appointment of experienced industry leader Scott Mendel as Chairman
- Mendel's extensive background in diagnostics and healthcare technology
- Retention of founding Chairman Robert Shepler on the board, ensuring continuity
- None.
MARLBOROUGH, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), the Spatial Biology Company®, today announced Scott Mendel has been appointed as Chairman of its Board, effective October 2, 2024. Mr. Mendel succeeds Robert Shepler, founding Chairman, who will remain on Akoya’s board. Mr. Mendel has served as a member of Akoya’s board of directors since June 2021 and has over 30 years of financial and operational management experience.
“I am thrilled to continue working with Akoya’s Management Team to capitalize on the Company’s leadership position in Spatial Biology. I intend to leverage my public company experience to assist in delivering on Akoya’s potential and maximizing shareholder return,” said Mr. Mendel.
Mr. Mendel, a leader in the diagnostics industry, previously served as President and Chief Executive Officer and a member of the board of directors of GenMark Diagnostics, Inc., a publicly traded molecular diagnostics company, from May 2020 until its acquisition by Roche in April 2021 for
“Having been involved with Akoya since its start-up in 2015 as one of its founding investors and a board member, I felt it was time to transition the Chairman’s role to such a talented executive as Scott. I am proud of what the Akoya team has achieved to date and very excited about its future prospects with Scott’s leadership as Chairman,” said Mr. Shepler.
“Scott’s long and successful history of operational leadership, coupled with his experience advising multiple companies in the tools and diagnostics industry makes him an ideal person for this role. I look forward to working even more closely with Scott to continue to ensure Akoya makes a positive impact for all stakeholders,” said Brian McKelligon, CEO of Akoya Biosciences.
Forward-Looking Statements
This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our prospects, our position in the spatial biology market, our ability to maximize shareholder return and other statements regarding our business strategies, results of operations, performance and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.
About Akoya Biosciences
As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The Company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode™ Panels and PhenoCycler®, PhenoImager® Fusion and PhenoImager HT Instruments. To learn more about Akoya, visit www.akoyabio.com.
FAQ
Who is the new Chairman of Akoya Biosciences (AKYA)?
What is Scott Mendel's background before joining Akoya Biosciences (AKYA)?
When did Scott Mendel join Akoya Biosciences' (AKYA) board of directors?
Who did Scott Mendel replace as Chairman of Akoya Biosciences (AKYA)?
